Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036708 | 0.87 | CHRM1 (0.65) | CHRM1CHRM2CHRM4CHRM5CHRNB2 | |
| SCHEMBL19114956 | 0.86 | GAA (0.46) | CHRM1CHRM2CHRM4CHRM5CHRNB2 | |
| SCHEMBL6313803 | 0.86 | MEN1 (0.46) | CHRM1CHRM2CHRM4CHRM5CHRNB2 | |
| Hydrochloric Acid SCHEMBL8397227 | 0.85 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM5CHRNB2 | |
| Hydrochloric Acid SCHEMBL29812700 | 0.85 | TSHR (0.45) | CHRM1CHRM2CHRM4CHRM5CHRNB2 | |
| SCHEMBL16844976 | 0.85 | CHRM2 (0.42) | CHRM1CHRM2CHRM4CHRM5CHRNB2 | |
| SCHEMBL65053 | 0.83 | SCN5A (0.39) | CHRM1CHRM2CHRM4CHRM5CHRNB2 | |
| SCHEMBL15689451 | 0.83 | ALDH1A1 (0.44) | CHRM1CHRM2CHRM4CHRM5CHRNB2 | |
| SCHEMBL7056593 | 0.80 | CHRM1 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRNB2 | |
| SCHEMBL19123576 | 0.80 | CHRNB2 (0.38) | CHRM1CHRM2CHRM4CHRM5CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4223285-A2 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | Novartis AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| EP-3169309-B1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS AG (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-10-06 | — | — | US | disclosed |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-08-04 | — | — | US | disclosed |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-7692026-B2 | crystal structure; photosensitivity; cyan couplers | FUJIFILM CORPORATION (JP) | 2010-04-06 | — | — | US | disclosed |
| US-7692026-B2 | crystal structure; photosensitivity; cyan couplers | FUJIFILM CORPORATION (JP) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | POLN, POLRMT, RNGTT | CHRM1 4884/4885CHRM2 4880/4885CHRM4 4859/4885 |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | CHRM1 2163/4885CHRM2 2684/4885CHRM4 2409/4885 |
| US-10729775-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | CHRM1 2163/4885CHRM2 2684/4885CHRM4 2409/4885 |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | CHRM1 2163/4885CHRM2 2684/4885CHRM4 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.